iSERA Lifesciences H1FY27 Results (BSE: 534920)
Signal: Steady quarter
The read
The key inflection is loss narrowing to 13.11 lakh from 33.62 lakh in the comparative period, but trajectory quality remains weak because operating revenue was not disclosed and the entire 7.88 lakh of reported income was other income; newly added fixed assets of 37.76 lakh have yet to translate into disclosed operations.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹0.08 Cr | N/A | N/A |
| Net profit | ₹-0.13 Cr | N/A | |
| EPS | ₹-0.62 | N/A |
P&L walk
Standalone total income was 7.88 lakh, entirely from other income because operating revenue was not disclosed; expenses of 20.99 lakh produced a 13.11 lakh loss and EPS of negative 0.62.
Key positives
- Net loss narrowed to 13.11 lakh from 33.62 lakh in the comparative period, while basic EPS improved to negative 0.62 from negative 1.60 in the printed comparison.
- Property, plant and equipment was reported at 37.76 lakh after 38.48 lakh of fixed-asset and capital-work-in-progress investment, establishing an asset base for future operations.
Key concerns
- No revenue from operations was disclosed; the entire reported total income of 7.88 lakh was other income, so the filing does not demonstrate operating traction.
- Administrative expenses of 16.09 lakh were nearly twice other income of 7.88 lakh, leaving a net loss of 13.11 lakh.
- Cash and cash equivalents fell to 3.55 lakh from 75.59 lakh despite reported operating cash flow of 116.86 lakh, with financing cash outflow of 158.30 lakh also reported.
Research and educational content only. Not investment advice.